Клинический анализ воспалительных заболеваний поверхности глаза после перенесенной SARS-CoV-2 инфекции и эффективность их лечения иммуномодулятором Имунофан

Abstract

Purpose. To present clinical information about the results of our own observations of inflammatory diseases of the eye surface after a SARS-CoV-2 infection and the effectiveness of complex treatment, including the domestic regulatory peptide Imunofan. Material and methods. There were 19 patients (38 eyes) under observation – 12 women and 7 men, aged from 22 to 57 years. Clinically, all patients had corneal syndrome and redness of the eyes. The control group consisted of 10 people who received standard anti-inflammatory, keratoprotective and desensitizing therapy. The main group included 9 people who, in addition to the standard treatment regimen, received parabulbar injections of Imunofan (50 mcg every other day) in the amount of 10 injections. Before treatment, in order to substantiate the pathogenetic expediency of Imunofan administration, immunoregulatory index (IRI) was calculated. Evaluation of treatment results was carried out on 5, 7, 10 and 20 days of treatment with the calculation of the total index of inflammation. Results. According to the results of the examination, the predominant clinical forms of postcovid inflammation of the eye surface were epithelial keratitis (57.8 %) and keratoconjunctivitis (26.3 %). The results of immunological monitoring of blood serum at the time of the initial visit to the ophthalmologist showed that all patients had IRI changes, while most of them (73.6 % of people) had secondary immune insufficiency, 5 people (26.4 %) had autoimmune disorders. The obtained data substantiate the expediency of using immunomodulators in pathogenetic treatment of this category of patients. Carrying out complex therapy, including the regulatory peptide Imunofan, led to a significant reduction in the symptoms of inflammation by the 7th–10th day of treatment, the timing of complete relief of the inflammatory process was reduced by almost two times. Conclusions. The occurrence of postcovid inflammation of the eye surface with disorders of the immune system is caused by pathogenetic relationships of SARS-CoV-2 infections, and developing by the type of secondary immune insufficiency (73.6 %), or autoimmune disorders (26.4 %). The use of Imunofan in the complex therapy of patients with an inflammatory process of the eye surface after a SARS-CoV-2 infection reduces the time of its relief by two times. Keywords: SARS-CoV-2 infection, inflammatory process of the eye surface, immunomodulator Imunofan